This study is in progress, not accepting new patients
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Santa Monica, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Joel Hecht
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Joel Hecht
Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- NGM Biopharmaceuticals, Inc
- ID
- NCT04913337
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 179 study participants
- Last Updated